Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements study located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://atozbookmarkc.com/story20608148/the-2-minute-rule-for-conolidin-to-replace-traditional-painkillers